[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575473":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Hyogo Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional treatments with middle meningeal artery embolization","EXPERIMENTAL",null,[13],"Procedure: Middle meningeal artery embolization",{"label":15,"type":16,"description":11,"interventionNames":11},"Conventional treatments alone","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"PROCEDURE","Middle meningeal artery embolization","Middle meningeal artery embolization within 7 days after randomization",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Kazutaka Uchida, MD, PhD","CONTACT","81+798-45-6458","fu-sakakibara@hyo-med.ac.jp",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Nishinomiya","Hyōgo","663-8501","Japan",{"type":37,"coordinates":38},"Point",[39,40],135.33199,34.71562,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":44,"phoneExt":11,"email":28},"+81-798-45-6458",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Kazutaka Uchida","Associate Professor (Stroke Center)","100575473",false,"NCT06772740","Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma","Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma (COMPLEMENT Study)","Inclusion Criteria:\n\n1. Age \\>=18\n2. pre-mRS 0-3\n3. Hematoma thickness \\>=10mm\n4. Having at least one risk factor Risk factor: Age \\>=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score \\>3, Preoperative volume \\>=130ml, Preoperative midline shift \\>=8mm, CT appearance (Homogeneous, laminar or separated)\n\nExclusion Criteria:\n\n1. Cr \\>=1.8\n2. Plt \\\u003C50,000, PT-INR \\>2\n3. Life expectancy \\\u003C6 months","ALL","18 Years",{"count":58,"type":59},600,"ESTIMATED","INTERVENTIONAL",[62],"NA","COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.",[65,66],"Endovascular Treatment","Chronic Subdural Hematoma","2025-05-26",{"date":69,"type":70},"2025-05-28","ACTUAL",{"date":72,"type":70},"2024-12-23",{"date":74,"type":59},"2029-03-31",{"name":47,"class":6},1]